buprenorphine and Radiodermatitis

buprenorphine has been researched along with Radiodermatitis* in 1 studies

Other Studies

1 other study(ies) available for buprenorphine and Radiodermatitis

Article	Year
The use of transdermal buprenorphine to relieve radiotherapy-related pain in head and neck cancer patients. Cancer investigation, 2013, Volume: 31, Issue:6 Many head and neck cancer (HNC) patients experience painful therapy-related mucositis and dermatitis. This prospective observational study evaluated transdermal buprenorphine use in HNC patients to relieve treatment-related pain. During treatment with paracetamol or tramadol, visual analogue scale (VAS)-pain scores >30/100 occurred in 26/45 patients 4 weeks after starting cancer therapy, persisting for ≥2 weeks after treatment. These patients subsequently received transdermal buprenorphine. Pain therapy should be more accurately up-titrated to the maximum recommended dose (140 μg/hr) where necessary to maintain pain scores ≤30/100 and, for some patients, should be continued for 6 weeks after the last cancer treatment day. Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Buprenorphine; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucositis; Pain; Pain Management; Pain Measurement; Prospective Studies; Radiation Injuries; Radiodermatitis	2013

Article

Year

The use of transdermal buprenorphine to relieve radiotherapy-related pain in head and neck cancer patients.

Cancer investigation, 2013, Volume: 31, Issue:6

Many head and neck cancer (HNC) patients experience painful therapy-related mucositis and dermatitis. This prospective observational study evaluated transdermal buprenorphine use in HNC patients to relieve treatment-related pain. During treatment with paracetamol or tramadol, visual analogue scale (VAS)-pain scores >30/100 occurred in 26/45 patients 4 weeks after starting cancer therapy, persisting for ≥2 weeks after treatment. These patients subsequently received transdermal buprenorphine. Pain therapy should be more accurately up-titrated to the maximum recommended dose (140 μg/hr) where necessary to maintain pain scores ≤30/100 and, for some patients, should be continued for 6 weeks after the last cancer treatment day.

Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Buprenorphine; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucositis; Pain; Pain Management; Pain Measurement; Prospective Studies; Radiation Injuries; Radiodermatitis

2013